Skip to main content
. 2023 Oct 2;6:100213. doi: 10.1016/j.ijpx.2023.100213

Table 2.

In-vitro release testing of RSNP Formulations.

Formulation
Code
Amount Released (%)
Release Model
Q24h Q4w Zero
Diffusion
Korsmeyer-Peppas
r2 r2 r2 k n
RSNP1 30.13±0.40 95.31±1.67 0.859±0.007 0.971±0.001 0.984±0.006 7.298±0.027 0.404±0.002
RSNP2 27.29±2.36 98.72±0.52 0.891±0.002 0.984±0.002 0.987±0.005 6.730±0.108 0.417±0.004
RSNP3 32.00±2.44 90.52±1.22 0.869±0.011 0.974±0.007 0.989±0.003 10.000±2.353 0.343±0.043
RSNP4 32.67±1.75 96.61±0.36 0.877±0.008 0.971±0.005 0.972±0.018 9.369±0.458 0.358±0.010
RSNP5 28.59±0.58 86.28±9.47 0.866±0.007 0.976±0.004 0.976±0.003 10.170±1.224 0.334±0.005
RSNP6 31.18±0.16 89.92±1.58 0.826±0.018 0.956±0.007 0.978±0.001 9.827±0.070 0.351±0.005
AL-RSNP 22.56±2.11 81.52±4.81 0.842±0.013 0.968±0.005 0.986±0.004 6.399±0.106 0.408±0.006

Abbreviations: RSNP, Rosuvastatin-entrapped silica nanoparticles; AL-RSNP, Alginate-loaded rosuvastatin-entrapped silica nanoparticles; Q24h, % drug released after 24 h; Q4w, % drug released after 4 weeks.

The composition of the prepared RSNP is found in Table 1. AL-RSNP is composed of Alginate matrix loaded with the selected Rosuvastatin-entrapped silica nanoparticle (RSNP2).